Allergen immunotherapy: Therapeutic vaccines for allergic diseases - A WHO position paper

Journal of Allergy and Clinical Immunology

Volumn 102, Issue 4 II, 1998, Pages 558-562

  Bousquet, Jean ^a   Lockey, Richard ^a   Malling, Hans Jorgen ^a   Alvarez Cuesta, Emilio ^b   Canonica, Giorgio W ^b   Chapman, Martin D ^b   Creticos, Peter J ^b   Dayer, Jean Michel ^b   Durham, Stephen R ^b   Demoly, Pascal ^b   Goldstein, Robert J ^b   Ishikawa, Takeru ^b   Ito, Koji ^b   Kraft, Dietrich ^b   Lambert, Paul Henri ^b   Løwenstein, Henig ^b   Müller, Ulrich ^b   Norman, Philip S ^b   Reisman, Robert E ^b   Valenta, Rudolph ^b   Valovirta, Erkka ^b   Yssel, Hans ^b   more..

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; VACCINE;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ANAPHYLAXIS; BEE STING; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOTHERAPY; INTRANASAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHINOCONJUNCTIVITIS; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION; WORLD HEALTH ORGANIZATION;

EID: 0031736285     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(98)70271-4     Document Type: Article

References (58)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1:1572-3.
2. Bousquet J, Müller UR, Dreborg S, Jarisch R, Mailing JH, Mosbech H, et al. Immunotherapy with Hymenoptera venoms. Position paper of the Working Group on Immunotherapy of the European Academy of Allergy and Clinical Immunology. Allergy 1987;42:401-13.
3. The current status of allergen immunotherapy (hyposensitisation). Report of a WHO/IUIS working group. Allergy 1989;44:369-79.
4. Current status of allergen immunotherapy. Shortened version of a World Health Organisation/International Union of Immunological Societies Working Group Report. Lancet 1989;1:259-61.
5. Mailing H, Weeke B. Immunotherapy. Position Paper of the European Academy of Allergy and Clinical Immunology. Allergy 1993;48(suppl 14):9-35.
6. Muller U, Mosbech H. Position paper: immunotherapy with Hymenoptera venoms. Allergy 1993;48(suppl 14):37-46.
7. International Asthma Management Project. International Consensus Report on Diagnosis and Management of Asthma. Allergy 1992;47:1-61.
8. Global strategy for asthma management and prevention. WHO/NHLBI workshop report. National Institutes of Health, National Heart, Lung and Blood Institute; 1995. Publication No.: 95-3659.
9. International Consensus Report on the Diagnosis and Management of Rhinitis. Allergy 1994;49(suppl 19):l-33.
10. Frew AJ. Injection immunotherapy. British Society for Allergy and Clinical Immunology Working Party. Br Med J 1993;307:919-23.
11. Nicklas R, Bernstein I, Blessing-Moore J, Fireman S, Gutman A, Lee R, et al. Practice parameters for allergen immunotherapy. J Allergy Clin Immunol 1996;6:1001-11.
12. Creticos P, Lockey R. Immunotherapy practice. Guide to current procedures. Milwaukee (WI): American Academy of Allergy, Asthma & Immunology; 1994, p. 1-77.
13. Dreborg S, Frew A. Allergen standardization and skin tests. EAACI Position Paper. Allergy 1993;48(suppl 14).
14. American Academy of Allergy, Asthma and Immunology. The use of standardized allergen extracts. J Allergy Clin Immunol 1997;99:583-6.
15. Nelson HS, Ikle D, Buchmeier A. Studies of allergen extract stability: the effects of dilution and mixing. J Allergy Clin Immunol 1996;98:382-8.
16. Norman PS, Lichtenstein LM. The clinical and immunologic specificity of immunotherapy. J Allergy Clin Immunol 1978;61:370-7.
17. Golden DB, Meyers DA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy. J Allergy Clin Immunol 1982;69:489-93.
18. Van-der-Zee JS, Aalberse RC. The role of IgG in immediate-type hypersensitivity. Eur Respir J Suppl 1991;13:91s-6s.
19. Varney VA, Hamid QA, Gaga M, Ying S, Jacobsen M, Frew AJ, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92:644-51.
20. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178:2123-30.
21. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187-94.
22. Hedlin G, Silber G, Naclerio R, Proud D, Lamas AM, Eggleston P, et al. Comparison of the in-vivo and in-vitro response to ragweed immunotherapy in children and adults with ragweed-induced rhinitis. Clin Exp Allergy 1990;20:491-500.
23. Bousquet J, Becker WM, Hejjaoui A, Chanal I, Lebel B, Dhivert H, et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a doubleblind, placebo-controlled, specific immunotherapy with standardized extracts. J Allergy Clin Immunol 1991;88:43-53.
24. Muller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992;89:529-35.
25. Bousquet J, Michel FB. Specific immunotherapy in asthma: Is it effective? J Allergy Clin Immunol 1994;94:1-11.
26. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C, Blanco-Quiros A. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol 1994;93:556-66.
27. Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990;85:460-72.
28. Mailing HJ, Dreborg S, Weeke B. Diagnosis and immunotherapy of mold allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy 1986;41:507-19.
29. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials [see comments]. Am J Respir Grit Care Med 1995;151:969-74.
30. Van-Metre TEJ, Adkinson N Jr, Lichtenstein LM, Mardinay M Jr, Norman P, Rosenberg GL, et al. A controlled study of the effectiveness of the Rinkel method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol 1980;65:288-97.
31. Bousquet J, Des-Roches A, Paradis L, Dhivert H, Michel FB. Specific immunotherapy in house dust mite allergy. Clin Rev Allergy Immunol 1995;13:151-9.
32. Carreira J, Lombardero M, Ventas P. New developments in in vitro methods. Quantification of clinically relevant allergens in mass units. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1994;87:155-64.
33. Creticos PS, Van-Metre TE, Mardiney MR, Rosenberg GL, Norman PS, Adkinson N Jr. Dose response of IgE and IgG antibodies during ragweed immunotherapy. J Allergy Clin Immunol 1984;73:94-104.
34. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993;91:709-22.
35. Olaguibel J, Tabar A, Garcia-Figueroa B, Cortes C. Immunotherapy with standardized extract of Dermatophagoides pteronyssinus in bronchial asthma: a dose-titration study. Allergy 1997 In press.
36. Van-Metre TEJ, Marsh DG, Adkinson N Jr, et al. Immunotherapy for cat asthma. J Allergy Clin Immunol 1988;82:1055-68.
37. Creticos PS, Marsh DG, Proud D, Kagey-Sobotka A, Adkinson N Jr, Friedhoff L, et al. Responses to ragweed-pollen nasal challenge before and after immunotherapy. J Allergy Clin Immunol 1989;84:197-205.
38. Van-Metre TEJ, Adkinson N Jr, Amodio FJ, Kagey-Sobotka A, Lichtenstein LM, Mardiney M Jr, et al. A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol 1982;69:181-93.
39. Creticos PS, Reed CE, Norman PS, Khoury J, Adkinson N Jr, Buncher CR, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996;334:501-6.
40. Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978;299:157-61.
41. Ownby DR, Adinoff AD. The appropriate use of skin testing and allergen immunotherapy in young children [see comments], J Allergy Clin Immunol 1994;94:662-5.
42. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987;79:660-77.
43. Lockey RF, Turkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC. The Hymenoptera venom study. III. Safety of venom immunotherapy. J Allergy Clin Immunol 1990;86:775-80.
44. Stewart Gd, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992;90:567-78.
45. Lüderitz-Püchel U, May S, Haustein D. Zwischenfälle nach Hyposensibilisierung. Münch med Wschr 1996;138:129-32.
46. Committee on Safety of Medicines. Desensitizing vaccines. Br Med J 1986;293:948.
47. Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. III. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol 1989;83:797-802.
48. Norman P. Is there a role for immunotherapy in the treatment of asthma? Yes. Am J Respir Crit Care Med 1996;154:1225-8.
49. Barnes P. Is there a role for immunotherapy in the treatment of asthma? No. Am J Respir Crit Care Med 1996;154:1227-8.
50. Munir AK, Bjorksten B, Einarsson R, Schou C, Ekstrand-Tobin A, Warner A, et al. Cat (Fel d I), dog (Can f I), and cockroach allergens in homes of asthmatic children from three climatic zones in Sweden. Allergy 1994;49:508-16.
51. Mailing H. Local immunotherapy. EAACI-ESPACI Position Paper. Allergy 1998 In press.
52. Ferreira F, Hirthenlehner K, Briza P, Scheiner O, Kraft D, Breitenbach M, et al. Isoforms of atopic allergens with reduced allergenicity but conserved T cell antigenicity: possible use for specific immunotherapy. Int Arch Allergy Immunol 1997;113:125-7.
53. Yssel H, Fasler S, Lamb J, de-Vries JE. Induction of non-responsiveness in human allergen-specific type 2 T helper cells. Curr Opin Immunol 1994;6:847-52.
54. Ball T, Vrtala S, Sperr WR, Valent P, Susani M, Kraft D, et al. Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. J Biol Chem 1994;269:28323-8.
55. Visco V, Dolecek C, Denepoux S, LeMao L, Guret C, Rousset F, et al. Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet vl. J Immunol 1996;157:956-62.
56. Lebecque S, Dolecek C, Laffler S, Visco V, Denepoux S, Pin J, et al. Immunologic characterization of monoclonal antibodies which modulate human immunoglobulin E binding to the major birch pollen allergen Bet v 1. J Allergy Clin Immunol 1997;99:374-84.
57. Raz E, Tighe H, Sato Y, Corr M, Dudler JA, Roman M, et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A 1996;93:5141-5.
58. Fahy J, Fleming H, Wong H, Liu J, Su J, Reimann J, t al. The effect of an anti-IgE monoclonal antibody on the early and late phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;1828-34.